Notice of Interim Results

RNS Number : 1235E

Redx Pharma plc

04 May 2017

 

4 May 2017

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company")

Notice of Interim Results

Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that its interim results for the six months ended 31^st March 2017 will be announced on Wednesday 17^th May 2017.

Dr. Neil Murray, Chief Executive Officer, and Andrew Booth, Interim Finance Director, will host a presentation and conference call for analysts and investors at 12:30pm BST / 7:30am EDT on the day of results at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2R 7HG. The presentation for the call will be made available on the Company website (www.redxpharma.com) in advance of the call.

For further information, please contact:

Redx Pharma Plc
Neil Murray, Chief Executive Officer	T: [phone]
Karl Hård, Head of Investor Relations & Corporate Communications	T: [phone]
Cantor Fitzgerald Europe (Nomad & Broker)	T: [phone]
Phil Davies/ Michael Reynolds
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson
Consilium Strategic Communications	T: [phone]
Amber Fennell/ Matthew Neal/ Melissa Gardiner

About Redx Pharma Plc

Company website: www.redxpharma.com 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 

END

 

 

NORAJMBTMBBMTIR